Estimated effects on people, organizations, and industries in bills this legislator sponsored, cosponsored, or voted on. Includes bills they voted against.
These are assessments of legislative text, not measurements of realized outcomes or the legislator’s intent.
Loading policy effects…
This selection could not be loaded. Your current view is still available.
Potential benefit to Foreign finished-drug manufacturers
Lower costs
Loosens a compliance mandate, exemption, tariff provision: 3. Exemption from customs country of origin marking requirement Section 304 of the Tariff Act of 1930 (19 U.S.C. 1304) is amended by adding at the end the... In practical terms, health care providers and patients face compliance burden down (positive).
Potential benefits are effects assessed as favorable to the named group. Potential burdens impose costs, restrictions, risks, or lost opportunities on that group.
Mixed effects contain countervailing effects on the same group. Unclear effects have an undetermined direction. A group can have separate benefits and burdens; these are counted separately.
Counts describe the number of identified effects, not their size or public value. Bill and clause counts are distinct within each view. Shared evidence may appear under several groups or policy areas, so their counts should not be added together.
Historical bill versions are included. Clauses analyzed in different versions count separately. A bill’s current status does not establish that every analyzed provision was enacted.
Only direct effects with high or medium confidence in the policy-area assignment are included. Bills are connected through sponsorship, cosponsorship, or Yea/Nay votes; a vote against a bill does not reverse its assessed effects. Vote dates filter recorded votes and vote-linked bills; sponsorship remains included.
